These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20831295)

  • 1. Comparative effectiveness regulations and pharmaceutical innovation.
    Vernon JA; Golec JH; Stevens JS
    Pharmacoeconomics; 2010; 28(10):877-87. PubMed ID: 20831295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Looking at CER from the pharmaceutical industry perspective.
    Dubois RW
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S9-12. PubMed ID: 22578212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
    Brixner DI; Watkins JB
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S06-11. PubMed ID: 22663293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness research: does the emperor have clothes?
    Coulter ID
    Altern Ther Health Med; 2011; 17(2):8-15. PubMed ID: 21717820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and health care spending--implications for reform.
    Weinstein MC; Skinner JA
    N Engl J Med; 2010 Feb; 362(5):460-5. PubMed ID: 20054039
    [No Abstract]   [Full Text] [Related]  

  • 8. Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials.
    Mullins CD; Whicher D; Reese ES; Tunis S
    Pharmacoeconomics; 2010; 28(10):969-76. PubMed ID: 20831305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.
    Oderda GM; Balfe LM
    J Manag Care Pharm; 2011; 17(9 Suppl B):S19-24. PubMed ID: 22073936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating comparative effectiveness research into clinical practice: the UK experience.
    Walley T
    Drugs; 2012 Jan; 72(2):163-70. PubMed ID: 22268389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness research: a progress report.
    Sox HC
    Ann Intern Med; 2010 Oct; 153(7):469-72. PubMed ID: 20679544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Private manufacturers' thresholds to invest in comparative effectiveness trials.
    Basu A; Meltzer D
    Pharmacoeconomics; 2012 Oct; 30(10):859-68. PubMed ID: 22901018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pragmatist's guide to comparative effectiveness research.
    Chandra A; Jena AB; Skinner JS
    J Econ Perspect; 2011; 25(2):27-46. PubMed ID: 21595324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facts, fallacies, and politics of comparative effectiveness research: Part 2 - implications for interventional pain management.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E55-79. PubMed ID: 20119475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The politics of comparative effectiveness research: lessons from recent history.
    Sorenson C; Gusmano MK; Oliver A
    J Health Polit Policy Law; 2014 Feb; 39(1):139-70. PubMed ID: 24193612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The American Reinvestment and Recovery Act investment in comparative effectiveness research: lessons learned and implications for future investments.
    Dormer L; Greenfield S
    J Comp Eff Res; 2014 Nov; 3(6):559. PubMed ID: 25494558
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.